Mineralys Therapeutics, Inc. (MLYS) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 7 Buy, 1 Hold.
The consensus price target is $46.00 (low: $30.00, high: $56.00), representing an upside of 68.4% from the current price $27.32.
Analysts estimate Earnings Per Share (EPS) of $-3.71 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.66 vs est $-3.71 (beat +1.4%). 2025: actual $-2.29 vs est $-2.39 (beat +4%). Analyst accuracy: 97%.
MLYS Stock — 12-Month Price Forecast
$46.00
▲ +68.37% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Mineralys Therapeutics, Inc., the average price target is $46.00, with a high forecast of $56.00, and a low forecast of $30.00.
The average price target represents a +68.37% change from the last price of $27.32.
Highest Price Target
$56.00
Average Price Target
$46.00
Lowest Price Target
$30.00
MLYS Analyst Ratings
Buy
Based on 8 analysts giving stock ratings to Mineralys Therapeutics, Inc. in the past 3 months
EPS Estimates — MLYS
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.66
vs Est –$3.71
▲ 1.4% off
2025
Actual –$2.29
vs Est –$2.39
▲ 4.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — MLYS
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
